CRDF Stock Summary and Trading Ideas (Cardiff Oncology | NASDAQ:CRDF)

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Cardiff Oncology trades on the NASDAQ stock market under the symbol CRDF.

As of September 4, 2026, CRDF stock price climbed to $1.09 with 433,149 million shares trading.

CRDF has a beta of 2.86, meaning it tends to be more sensitive to market movements. CRDF has a correlation of 0.14 to the broad based SPY ETF.

CRDF has a market cap of $84.80 million. This is considered a Micro Cap stock.

Last quarter Cardiff Oncology reported $104,000 in Revenue and -$.14 earnings per share. This beat revenue expectation by $35,776 and exceeded earnings estimates by $.02.

In the last 3 years, CRDF traded as high as $6.42 and as low as $.76.

The top ETF exchange traded funds that CRDF belongs to (by Net Assets): VTI, VXF.

CRDF has underperformed the market in the last year with a return of -48.8%, while the SPY ETF gained +19.8%. In the last 3 month period, CRDF fell short of the market, returning -29.7%, while SPY returned +2.0%. However, in the most recent 2 weeks CRDF has outperformed the stock market by returning +23.8%, while SPY returned +0.6%.

CRDF support price is $1.03 and resistance is $1.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRDF shares will trade within this expected range on the day.